Your adrenal glands sit on top of your kidneys and run a tightly choreographed assembly line that turns cholesterol into cortisol, the hormone that manages your stress response, blood sugar, blood pressure, and immune function. 11-Deoxycortisol (also called Compound S) is the molecule that sits one step before cortisol on that assembly line. When everything works, it gets quickly converted to cortisol and barely accumulates. When the enzyme responsible for that final conversion is missing or blocked, 11-deoxycortisol piles up, and your cortisol output drops.
That makes this test a direct readout of one specific bottleneck in cortisol production. A high level points to a problem with the enzyme that finishes the job (called 11-beta-hydroxylase), while the response of 11-deoxycortisol to certain provocation tests can reveal whether your entire adrenal control system is intact. For people investigating unexplained hormone imbalances, high blood pressure with low potassium, or signs of excess androgen activity, this number fills a gap that cortisol alone cannot.
Your adrenal cortex produces cortisol through a series of enzyme-driven steps. An earlier enzyme called 21-hydroxylase converts a precursor (17-alpha-hydroxyprogesterone) into 11-deoxycortisol. Then a second enzyme, 11-beta-hydroxylase, performs the final conversion of 11-deoxycortisol into cortisol. This entire process is regulated by ACTH (adrenocorticotropic hormone), a signaling molecule released by the pituitary gland in your brain. When cortisol is low, the pituitary sends more ACTH to push the adrenals harder.
Under normal conditions, 11-deoxycortisol circulates at very low levels because it is efficiently converted to cortisol almost as fast as it is made. The test becomes informative when that conversion is impaired or when a drug deliberately blocks it to stress-test your system.
The single most important reason to measure 11-deoxycortisol is to diagnose or rule out 11-beta-hydroxylase deficiency, the second most common form of congenital adrenal hyperplasia (CAH). CAH is a group of inherited conditions where a faulty enzyme disrupts cortisol production. Because cortisol stays low, the pituitary floods the adrenals with ACTH, driving overproduction of the intermediates that pile up before the blocked step. In 11-beta-hydroxylase deficiency, that means 11-deoxycortisol and a related molecule called deoxycorticosterone accumulate, along with adrenal androgens (male-type hormones produced by the adrenal glands).
This condition accounts for 5 to 8% of all CAH cases. The classic form presents early in life: affected females are born with ambiguous genitalia in 100% of cases, and about two-thirds of all classic cases develop high blood pressure, sometimes with low potassium, driven by the buildup of deoxycorticosterone (which acts like a weak version of the blood-pressure-regulating hormone aldosterone). Adult height is significantly reduced, with average heights around 152 cm in females and 160 cm in males.
A milder, nonclassic form exists as well. It does not cause genital changes at birth or high blood pressure, but it can show up later with signs of excess androgens, such as acne, excess body hair, or irregular periods. About 19% of patients with 11-beta-hydroxylase deficiency are initially misdiagnosed as having the more common form of CAH (21-hydroxylase deficiency), which is why measuring 11-deoxycortisol specifically is so valuable for getting the diagnosis right.
The most common form of CAH, 21-hydroxylase deficiency, accounts for about 90 to 95% of cases. Its hallmark lab finding is a high level of 17-alpha-hydroxyprogesterone (the molecule that sits before the blocked enzyme step). In 21-hydroxylase deficiency, 11-deoxycortisol may be normal or only mildly elevated, because the block is upstream and less of the precursor material reaches the 11-deoxycortisol step.
The ratio between 11-deoxycortisol and 17-alpha-hydroxyprogesterone is the key to distinguishing the two conditions. A high ratio (11-deoxycortisol much higher than 17-alpha-hydroxyprogesterone) points toward 11-beta-hydroxylase deficiency. A low ratio points toward 21-hydroxylase deficiency. An 11-deoxycortisol-to-cortisol ratio above 2.2 has been shown to have 100% specificity for classic 11-beta-hydroxylase deficiency, meaning it virtually never gives a false positive.
Beyond diagnosing CAH, 11-deoxycortisol plays a central role in the metyrapone stimulation test, which is used to evaluate whether your hypothalamic-pituitary-adrenal (HPA) axis is working properly. Metyrapone is a drug that temporarily blocks the same 11-beta-hydroxylase enzyme, preventing cortisol production. In a person with a healthy HPA axis, the pituitary detects the cortisol drop and responds by increasing ACTH, which drives 11-deoxycortisol levels up.
A normal response is an 11-deoxycortisol level above 70 mcg/L (or above 200 nmol/L) roughly 8 hours after taking metyrapone. Failure to reach this threshold suggests that the pituitary or hypothalamus is not responding properly, pointing toward secondary adrenal insufficiency (also called central adrenal insufficiency). This test is also used to help distinguish Cushing's disease (excess cortisol driven by a pituitary tumor) from ectopic ACTH syndrome (excess cortisol driven by a tumor elsewhere in the body). In Cushing's disease, 11-deoxycortisol rises normally or excessively after metyrapone; in ectopic ACTH syndrome, it typically shows little response.
Baseline 11-deoxycortisol levels in healthy adults are normally quite low. The exact reference range varies by laboratory and assay method. Results are typically reported in ng/dL or nmol/L. Because this biomarker is primarily a diagnostic tool rather than a screening marker with established population-wide risk tiers, the most meaningful interpretation depends on clinical context: baseline levels in a healthy person versus levels measured during a stimulation test versus levels in someone being evaluated for CAH.
| Context | Expected Range | What It Suggests |
|---|---|---|
| Healthy baseline | Below approximately 50 ng/dL | Normal adrenal enzyme function; 11-deoxycortisol is being efficiently converted to cortisol |
| After metyrapone stimulation | Above 70 mcg/L (above 200 nmol/L) | Intact HPA axis; the pituitary is responding to cortisol suppression by driving precursor accumulation |
| Suspected 11-beta-hydroxylase deficiency | Markedly elevated, often many times above normal | The enzyme converting 11-deoxycortisol to cortisol is absent or severely impaired |
These values are drawn from published research and clinical guidelines. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful interpretation. The 11-deoxycortisol-to-cortisol ratio (above 2.2 indicating classic 11-beta-hydroxylase deficiency) may be more clinically useful than the absolute level alone.
Any medication that interferes with the adrenal glands' hormone-production process can alter your 11-deoxycortisol level. Metyrapone itself is the most obvious example: it is designed to block the enzyme and raise 11-deoxycortisol, so a measurement taken during or shortly after a metyrapone test does not reflect your body's natural state. If you are taking any steroid medications (such as prednisone or hydrocortisone), these can suppress ACTH and reduce adrenal precursor production, potentially lowering your 11-deoxycortisol reading.
Acute physical stress, severe illness, or recent surgery can transiently activate the HPA axis and alter steroid precursor levels. A single reading taken during a period of acute illness may not represent your baseline. Time of day also matters: cortisol and its precursors follow a circadian rhythm, peaking in the early morning and declining through the day. A morning blood draw is standard for consistent interpretation.
For most people, a single baseline 11-deoxycortisol measurement that falls in the normal range is reassuring, and serial monitoring is not necessary unless there is a clinical reason to repeat it. Where trending becomes valuable is in people already diagnosed with a form of CAH or adrenal insufficiency. In these cases, periodic measurement helps assess whether treatment (such as glucocorticoid replacement) is adequately suppressing ACTH-driven precursor accumulation without overreplacing cortisol.
If you are being evaluated for a possible enzyme deficiency or HPA axis problem, a single abnormal result should prompt a repeat measurement and, often, a formal stimulation test. The combination of a baseline level and a post-stimulation level gives a much clearer picture than either value alone. For anyone tracking this marker over time, use the same lab and same assay method at each draw. Different assay platforms can produce meaningfully different numbers for the same sample, so switching labs mid-stream can create the illusion of a change that is really just a measurement difference.
Evidence-backed interventions that affect your 11-Deoxycortisol level
11-Deoxycortisol is best interpreted alongside these tests.